Therapeutic vaccination for non-small-cell lung cancer: A meta-analysis

Medical Oncology

Volumn 31, Issue 4, 2014, Pages

  Ding, Mei ^a   Yang, Jiong ^a  

^a ZHONGNAN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Efficacy; Non small cell lung cancer; Therapeutic vaccination; Tolerability

Indexed keywords

CANCER VACCINE;

ANEMIA; ANOREXIA; ANTIBODY RESPONSE; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COUGHING; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSPNEA; FATIGUE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTE SUBPOPULATION; META ANALYSIS; NEUTROPENIA; OVERALL SURVIVAL; PLEURA EFFUSION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHINOPHARYNGITIS; RIGOR; THORAX PAIN; THROMBOCYTOPENIA; DISEASE FREE SURVIVAL; FOLLOW UP; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

CANCER VACCINES; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84898797036     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-014-0928-1     Document Type: Article

References (25)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893-917.
2. Yang P, Allen MS, Aubry MC, et al. Clinical features of 5,628 primary lung cancer patients: experience at the Mayo Clinic from 1997 to 2003. Chest. 2005;128:452-62.
3. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage grouping in the forthcoming (seventh) edition of the TNM classification of malignant tumors. J Thorac Oncol. 2007;2:706-14.
4. Kakimi K, Nakajima J, Wada H. Active specific immunotherapy and cell transfer therapy for the treatment of non-small-cell lung cancer. Lung Cancer. 2009;65:1-8.
5. Azzoli CG, Baker S Jr, Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27:6251-66.
6. Yasumoto K, Hanagiri T, Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 2009;57:449-57.
7. Chrischilles EA, Pendergast JF, Kahn KL, Wallace RB, Moga DC, et al. Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lunger cancer. J Clin Oncol. 2010;28:620-7.
8. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- pacilitaxel in pulmonary adenocarcinoma. NEJM. 2009;361(10):947-57.
9. Shaw AT, Yeap BY, Solomon BJ, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol. 2011;12:1004-12.
10. Limacher J-M, Spring-Giusti C, et al. Therapeutic cancer vaccines in the treatment of non-small-cell lung cancer. Exp Rev Vaccines. 2013;12:263-70.
11. Tyagi P, Mirakhur B. MAGRIT: the largest-ever Phase III lung cancer trial aims to establish a novel of tumor-specific approach to therapy. Clin Lung Cancer. 2009;10:371-4.
12. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
13. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12.
14. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ADo about nothing: a comparison of the performance of meta-analytical methods with rare event. Stat Med. 2007;26:53-77.
15. Cox DR. Regression models and life-tables. J R Stat Soc B (Methodological). 1972;B34:187-220.
16. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analysis of the published literature for survival endpoints. Stat Med. 1998;17:2815-34.
17. Butts C, Socinski MA, MItchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomized, double-blind, phase 3 trial. Lancet Oncol. 2014;15:59-68.
18. Vinageras EN, de la Torre A, Rodriguez MO, et al. Phase II randomized controlled trial of an Epidermal Growth Factor Vaccine in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26:1452-8.
19. O'Brien MER, Anderson H, Kaukel E, et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol. 2004;15:906-14.
20. Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011;12:1125-33.
21. Vansteenkiste J, Zielinski M, Linder A, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol. 2013;31:2396-404.
22. Reck M. Current approaches in chemotherapy of advanced and metastatic non-small-cell lung cancer (NSCLC). Anticancer Res. 2005;25:1501-6.
23. Ronan JK, Giuseppe G. Lung cancer-vaccines. Cancer J. 2011;17(5):302-8.
24. Strand LM, Morley PC, Cipolle RJ, et al. Drug-related problems-their structure and function. DICP Ann Pharmacother. 1990;24:840-6.
25. Butts C, Maksymiuk A, Goss G, et al. Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial. J Cancer Res Clin Oncol. 2011;137:1337-42.